Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–2 of 2 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: SMAD4 Clear all

Terminated Phase 2 Interventional Results available

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

NCT01921751

View directory record Official record

Conditions: Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer
Interventions: low intensity radiation therapy, Capecitabine, Gemcitabine, high intensity radiation therapy, nab-Paclitaxel; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 46
States / cities: Oakland, California • Santa Clara, California • South San Francisco, California + 39 more

Source: ClinicalTrials.gov public record

Updated Jul 12, 2018 · Synced May 21, 2026, 8:03 PM EDT

Recruiting Not applicable Interventional Accepts healthy volunteers

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

NCT05420064

View directory record Official record

Conditions: BRCA1 Mutation, POLD1 Gene Mutation, CDKN2A Mutation, BRCA2 Mutation, POLE Gene Mutation, APC Gene Mutation, ATM Gene Mutation, MLH1 Gene Mutation, BARD1 Gene Mutation, MSH2 Gene Mutation, BRIP1 Gene Mutation, MSH6 Gene Mutation, CHEK2 Gene Mutation, PMS2 Gene Mutation, PALB2 Gene Mutation, EPCAM Gene Mutation, RAD51C Gene Mutation, BMPR1A Gene Mutation, RAD51D Gene Mutation, SMAD4, PTEN Gene Mutation, GREM1
Interventions: Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 25 Years and older

Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Source: ClinicalTrials.gov public record

Updated Nov 11, 2025 · Synced May 21, 2026, 8:03 PM EDT